Press Room

Press Clipping / Dec 10, 2018

Life Sciences: Hovione increases production capacity while looking forward to its tenth year in Cork

Irish Examiner, December 10, 2018

2019 will be a very significant year for Hovione the contract pharmaceutical manufacturing company which helps bring new and off-patent drugs to market celebrates 10 years Irish-side.

Hovione which took over Pfizer’s former Loughbeg site in Ringaskiddy in 2009 has seen rapid growth over the last 10 years.

The company employs over 200 people in Cork and hundreds more at its other three sites spread over three continents with facilities in Lisbon (Portugal), Macau (China), New Jersey (USA).

Hovione has over 55 years of experience in the development and compliant manufacture of Active Pharmaceutical Ingredients and Drug Product Intermediates.

The Cork plant plays a significant and strategic role within the Hovione network and that was certainly proven earlier this year when Hovione expanded its production capacity.

Having recommissioned a third production building at their site in Ringaskiddy Hovione went into production at this building in May of this year.

“This is the first time in Cork’s history that all three buildings have been running at the same time”, said General Manager Paul Downing who said it is an exciting time in the company’s history as Hovione Cork now have extensive manufacturing capacity with two Active Pharmaceutical Ingredient facilities alongside a Drug Product Intermediate facility that houses the largest, commercial pharmaceutical spray dryer in operation.

Dr Downing said he is optimistic about the future.

2019 he said is going to be a really big year for Hovione Worldwide as it celebrates its 60th Anniversary. 

The company was founded by Ivan Villax with his wife Diane Villax in Lisbon in Portugal in 1959.

“We have a very ambitious plan to be the Number 1 innovative, integrated pharmaceutical solution provider to the global pharmaceutical industry by 2028,” said Dr Downing. 


Our mission is to passionately turn any challenge into a solution by collaboration with our partners to develop great medicines.


"That is a company corporate goal so that requires all our facilities to grow and expand so this expansion plan is across the whole Hovione network including Lisbon, New Jersey, Macau and also obviously Cork.

“In short we give our customers what they cannot find elsewhere”, says Dr. Downing, who explains that the company’s customers come from the sectors of biotechnology, medium, speciality and large pharmaceuticals as well as generics pharmaceuticals.

“Hovione has a unique value proposition. We have more than 15 years of experience in pharmaceutical spray drying and have produced hundreds of batches for clinical trials and commercial supplies.

“We have a very diverse workforce. We currently have 15 nationalities onsite here in Cork. 

"Hovione is a fast, challenging dynamic environment and there are great opportunities for people with all skill sets at whatever age.

“Because the market demands different products you can work on multiple products and multiple projects at the same time. That gives people a diversity of experience. 

"We like to have a balance between promoting from within and recruiting from outside so therefore if someone has the desire to move within the organisation these opportunities arise.”

Hovione is constantly developing its talent pool and is a big supporter of and encourages apprenticeships for young people where they get an opportunity to gain very substantial and important skills allowing them to take up roles as electricians, fitters, quality control analysts, instrument technicians as well as automation technicians.

The Apprenticeship programme not only provides participants with the necessary technical and professional skills, it also provides valuable teamwork experience.

Valuable teamwork experience

“What we do find is that people can have very strong technical and academic skills but their team collaboration skills require us to invest in further training. 

"These skills would be automatically instilled in participants in the Apprenticeships programmes. 


In complex and large organisations like ourselves the interpersonal skills and an ability to work in small teams is important.


Hovione works with Skillsnet and other local academic institutions to help build capabilities that can take advantage of the many career opportunities available.

“We do College site tours and Master student placements. We work with the IDA on the IBEC EOP Programme which sees graduates spend six months with us and six months with our sister facility in Portugal mostly working as process engineers or QC analysts. 

"We hope these graduates will come and join us in our new process in Cork in 2019.

“We continue to work with the Portuguese Postdoctoral Graduate Placement Programme and with the Cork Education Training Board and this year we supported the IBEC Laboratory Apprenticeship Programme — we have the first two apprentices joining from that initiative this January in collaboration with CIT so we look forward to that as it has been a couple of years in the making.”

Overall, Hovione’s steadfast growth is the result of an integrated synergy that allows the company to serve both the global markets and also to respond to specific customer demands when necessary.

The company has a solid legacy of Corporate Social Responsibility — last year Hovione became a Certified B Corp – becoming the first facility in Ireland to have received this certification.

The company’s ‘Safety First, Quality Always’ culture is also something staff are very proud of - “we nurture it each day so that we do not take it for granted”.

“In the coming years we will continue to invest in additional capability and hire additional team members, launch and validate more new products”, says Dr Downing, who points out that the company is an active member of Biopharmachem Ireland, Cork Chamber as well as Business in the Community Ireland.

Hovione sponsors and supports local community initiatives as well as establishing crucial links with the academic and training institutions through its support of STEM — initiatives to encourage take-up of subjects such as science, technology, engineering and mathematics — as well as CIT Student placements and the Cork Training Centre.

Just last week, Hovione won the Corporate Citizen Responsibility Business in Community Ireland Mark.

Carbon footprint commitment

“We are one of 40 leading companies who have signed up to significantly reduce their carbon emissions between now and 2030”.

The pledge was made at a summit organised in Dublin last week by Business in the Community in Ireland, which describes itself as a network for sustainability.

“We are the first contact manufacturing organisation to win that award,” said Dr Downing. 

“We see that things like corporate social responsibility, being ethical in the workplace and within the community, reducing our carbon footprint are all important very important issues going forward.”

Hovione committed to engaging with its local communities

Hovione holds annual corporate social responsibility days and each year a particular organisation is chosen.

This year, the company supported SIMON Community — fundraising and giving practical support. Every Christmas, the company also facilitates food and gift appeals for the Society of St Vincent de Paul.

Dr Paul Downing said: “We are the first chemical / pharmaceutical company integrating this innovative community of companies that use the power of business to solve social and environmental problems. 

"As a Certified B Corporation, we want to contribute to redefine success in business meeting the highest standards of social and environmental performance, setting out Team Members for success and personal satisfaction and aspiring to use the power of markets to solve social and environmental problems.


This is a global movement of people using business as a force for good, with a vision that one day all companies compete not only to be the best in the world but the best for the world.


As well as expansion in Cork, Hovione is completing by the end of 2018 the qualification of its continuous tableting line at New Jersey (USA)

The capacity expansion program started in 2016 and will continue in the coming five years. 

Hovione has relocated its development services to a new centre with 7,000 m2 in Lisbon — fully equipped with the most recent tools to handle potent and highly potent compounds.

The Loures site expanded its drug substance reaction vessel capacity with a small-scale production area and a new pilot plant. 

The company installed more spray drying capacity at the site and started the operation of a new drug product centre equipped with oral dosage form as well as inhalation manufacturing capabilities. 

In New Jersey, Hovione has doubled the size of its development and manufacturing operations.

The decision to expand follows growing customer demand since Hovione started offering end-to-end solutions from drug substance to drug product from the Loures site in 2017.

Hovione increased production capacity in oral dosage forms in Portugal to strengthen their integrated offering. 

New commercial scale equipment for blending, tableting and coating will complement existing development small scale equipment. 

This ‘One Site Shop’ allows customers to streamline their supply chain, reduce time to market and benefit from seamless project management. 

This increase in capacity helps Hovione customers to consistently bring products to market faster.

Paul looks forward to a very exciting year ahead. 

All these successes here at home, he says, would not have been possible without the continued support of the local businesses, IDA, Biopharmachem Ireland and the staff working at the Cork facility.

 

Read the full article

 

Also in the Press Room

See All

The CDMO is preparing for its New Jersey facility to become fully operational this year. Hovione’s multimillion-dollar investment in expanding its East Windsor, NJ manufacturing site is quickly coming to fruition. Contract Pharma will be visiting the site later in April 2026 to provide a unique overview of what’s new. As a preview, the Contract Pharma team met with Hovione at the Drug, Chemical & Associated Technologies Association (DCAT) Week. David Basile, Vice President of Technical Operations—Americas, spoke at the opening Member Company Announcement Forum on March 23, 2026. In this interview, Basile expands on his remarks at the Announcement Forum. As he explains, Hovione is concentrating not only on New Jersey, but also on facilities in Ireland and Portugal. Contract Pharma: Good manufacturing practice (GMP) operations will soon be fully operational at the New Jersey facility. How has Hovione progressed through this process since the initial investment cycle was announced last fall—or even prior? David Basile: It’s been a really great journey and evolution over the last two to three years, conceiving the plan to grow our U.S. footprint. It was one of the reasons I came aboard with Hovione, to grow that footprint and build our commercial manufacturing prowess in the States. In New Jersey, we had originated [the site] as a tech transfer center. [But] we wanted to grow the organization to be more equivalent with our Portugal and Ireland sites, to do more large-scale manufacturing. So, this is part of that journey. And that’s not just bricks-and-mortar and machinery. It’s been people, talent, partnerships with clients, supporting functions such as QC [quality control] and analytical development. We’re growing our R&D teams as well. It’s a comprehensive approach to systems, people, and processes. CP: At the Member Company Announcement Forum, you ran through some of the major technical specifications of the NJ expansion. Can you talk about a few of the highlights and their capabilities? Basile: This year we’ll be starting up two PSD-3 scale spray dryers. This is a useful scale of machinery for our clients. It plays nicely between the PSD-2 and PSD-4 scales that we have elsewhere in the network. I’d say it’s medium-to-large scale capacity; we could do 30 metric tons annually out of this type of a unit. Product to product, that differs, but we do have products that put that kind of volume out in a PSD-3, so it’s not small-scale. Customers want to hear this because [they want to gain] efficiency with their batch size, and turnaround time. And when we campaign, we can really see significant throughput with this line up of new machinery and assets. The first machine that we will start up is a Hastelloy unit, which is unique. We took a pause [in the construction timeline] to make that upgrade, as we had a client that needed this configuration. There are additional clients that are interested in it too, because you can do acidic solutions and more aggressive kinds of formulations as well as solvent-based formulations. So that’s a unique element of that first machine. The second machine is being qualified later this year. Kind of a twin, but this one is standard 316 stainless steel.  CP: When a company brings a new or expanded facility online, new personnel often accompanies the new tech. What is the workforce addition that you expect, and what are the challenges of retaining top talent? Basile: In preparation for commissioning and startup of this new equipment, we’ve already ramped our headcount up, to be ready for GMP launch. We’ve added roughly 20 employees in preparation for this first machine to go [live]. Over the next 18-plus months, we could see something on a similar scale, getting us up to that 40–50 headcount range for that facility once it’s fully operational—and more later on in 2028, when we bring in the CDC [continuous direct compression] Flex unit. That’s what’s really going to be transformative about this new facility: that integrated offering coming to life. CP: Even if the NJ facility is top of mind right now, let’s also touch on some of your plans in Europe. What is your vision for expanding in Europe in the next two to three years? Basile: Ideally, Hovione’s aim is to build an equivalent manufacturing network, where clients can go to any site across the globe and get a similar breadth and scale of offering. We’re doing that now in Ireland, expanding our PSD-4 scale spray drying. One unit was recently installed. Late last year, it went live. Then there’s at least one other new PSD-4 in motion, which is really exciting, because [spray dryers] at this site were historically [exclusive to] larger chemistry manufacturing for API [active pharmaceutical ingredient] synthesis. So now, they’re further building their muscle with additional large scale spray drying capacity. On the Portugal side, there’s a lot of great things going on. Our Tejo campus, in Seixal, Portugal, is a massive, 4.5-million-square-foot plot of land, and there’s a new, modular facility going up there. It’s incredibly exciting. The design of the facility has been well-thought through with material flows [and] gravity-fed processes. Here, we minimize handling and [maximize] speed of processing. It’s scalable. We call each one of these building segments a finger. You can copy and paste these fingers, and they are built to house both spray drying and drug product assets within each unit. So, why is that relevant? Because we can easily scale the number of fingers. When customers say, “we need more capacity,” we have the design on the table ready to go. We know how to execute, we know how to build and implement our technology platforms in a short timeframe. Deployment timeframes are truly becoming more and more relevant to our clients. CP: From last year’s DCAT Week to this year’s, what conversations are you having with industry colleagues about ever-changing geopolitics? Basile: We’re seeing that local, regional manufacturing capacity is vital. The concept of U.S. for U.S. and China for China seems to be a common theme that our clients are talking about. We happen to have an edge, as we [have already] started our journey of expanding our domestic U.S. capacity. So I think that’s a crucial piece to the puzzle, having dual-sided Atlantic manufacturing operations. The traditional global supply chain model is being challenged. Having soup-to-nuts sites that are fully autonomous in development, scale-up, tech transfer, all the way to commercial scale operation, is vital to Hovione, and how we’re protecting our supply chain. [Concerning] starting raw materials and Tier 2 suppliers, our procurement teams are out in the market making sure that there’s no single point of failure for critical materials [like] polymers and solvents that we utilize. We’re managing and mitigating risk by looking at those secondary suppliers across different geographies. CP: Encapsulating your planned expansions on both sides of the Atlantic, how would you sum up the value to the customer? Basile: It’s about speed-to-market. It’s one partner from early-phase development, clinical scale, all the way through commercial. They gain comfort, trust, and not just capacity and equipment time; it’s also about competency and depth of scientific expertise. We’re not just a traditional CDMO. There’s unique expertise in particle science and spray dried dispersions that we offer our clients that they don’t have. [With] traditional CDMOs, customers typically pay for time in [a particular] unit, for example, they’d say: “I need a machine, and I need [it for] three weeks.” Hovione is truly a partner to our clients. They’re leveraging our platforms, our know-how in spray drying, and our know-how in equipment design. Read the article at ContractPharma.com  

Article

Hovione Eyeing Manufacturing Expansion on Both Sides of Atlantic

Apr 06, 2026

With key expansions coming to fruition on either side of the pond, specialist CDMO Hovione is making sure that drugmakers can access its particle engineering expertise across multiple geographies.  That flexibility will be key for the Portugal-based company in the coming years as the pharmaceutical industry continues to embrace more regional supply chains. In a recent interview, Hovione's David Basile, VP of technical operations for the Americas, discussed this trend and the manufacturer's expansion project, which is set to come online in New Jersey next month.  In the coming weeks, Hovione plans to debut a new spray drying expansion at its campus in East Windsor, New Jersey. The company has invested $100 million to expand its campus, including new construction and the acquisition of an additional facility and greenfield land.  Specifically, one of two pharmaceutical spray drying-3 units, or PSD-3 units, will come online in the coming weeks to tackle amorphous active pharmaceutical ingredients (APIs) and amorphous solid dispersions, according to the company. With some 80% of new small molecules in development insoluble in water, Hovione’s particle engineering and amorphous solid dispersion platform helps medicine developers improve the solubility, bioavailability, and, in some cases, the stability of their drug candidates, Basile said.  The company boasts spray dryers from the lab scale to PSD3 at its original facility in East Windsor, in addition to the pair of large-scale machines about to be activated at the campus' new facility.  “We’re going for a single, unified site with capabilities across the campus to do drug substance through finished drug product under one governance and quality system,” - Basile told Fierce.   Read the full article at FiercePharma.com

Article

As expansions come online, CDMO Hovione aims to meet industry's 'dual supply and sourcing' zeal: exec

Mar 26, 2026